🇺🇸 FDA
Pipeline program

BIIB122

283PD201

Phase 3 small_molecule active

Quick answer

BIIB122 for Parkinson Disease is a Phase 3 program (small_molecule) at Denali Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Denali Therapeutics
Indication
Parkinson Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials